PUNE : Adar Poonawalla, Chief Executive Officer (CEO) and owner of the Serum Institute of India (SII) on Monday assured Indians who have taken Covishield doses and are now facing issues while travelling to European Union countries that the matter had been escalated to the ‘highest level’.
In a tweet, Poonawala also said he hoped to resolve the matter soon, both with regulators and at a diplomatic level with countries.
“I realise that a lot of Indians who have taken COVISHIELD are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries,” he tweeted.
Read More
- Colombia earthquake death toll rises to 294 as rescue hopes fade
- Oman negotiations, reopening of Hormuz are two separate issues: Iranian FM Araghchi
- At least 47 killed, 157 homes damaged as Indonesia reels from devastation after three earthquakes
- H-1B visa extension fee unlikely to outweigh cost of losing skilled talent
- No decision yet on US talks, Iran says as Hormuz tensions rise
This comes after reports that travellers vaccinated with Covishield, the AstraZeneca-Oxford vaccine manufactured in India by the SII, may not be eligible for the European Union’s ‘Green Pass’.
Europe’s vaccine passport programme, which allowed recipients to travel to and from Europe with fewer roadblocks, may not recognise recipients of the Covishield vaccine.
Covishield is one of the three COVID-19 vaccines approved for use in India. (ANI)
Liked this story? We’ll send you more. Subscribe to TAS newsletter and get stories delivered to your inbox. Click to get started.
